Despite the controversy surrounding a relationship with departing director Alex Denner, Susan Langer has secured enough investor support to join Biogen’s board.

Erytech's merger with Pherecydes has reached the finish line after a contentious battle with an activist investor. The proposed merger was greenlighted by Erytech's shareholders, denying Akkadian Partners' request to reject it.

Next time a project hits a setback, think of Eversana Intouch’s Cannes gold lion winning campaign. The New York agency pivoted around a stumbling block that threatened to sink its campaign—and turned the hitch into a strength that bolstered its core message about the inequality of breast cancer care.

A range of study data presented by Medtronic at the American Diabetes Association’s annual scientific sessions over the weekend touts the benefits of its newly FDA-approved MiniMed 780G insulin pump technology for kids and teenagers.

The potential advantages of a daily-pill version of popular GLP-1 drugs for Type 2 diabetes and obesity are obvious compared to the weekly-injection routine most patients taking these drugs undergo. Last weekend at the American Diabetes Association Scientific Sessions in San Diego, market leaders Novo Nordisk and Eli Lilly presented data that showed their investigative oral GLP-1 treatments are making progress.

Investor Blackstone Life Sciences is paying Sutro Biopharma $140 million cash and throwing in another potential $250 million in biobucks in exchange for royalties on possible future sales of Vaxcyte’s products.

Lundbeck CEO Deborah Dunsire is retiring on a high note in the neuroscience company’s history. After hitting the company's highest quarterly revenue in the first quarter, the five-year Lundbeck chief executive will pass the baton to UCB's neurology head.

Gelesis’ oral hydrogel technology was cleared by the FDA in 2019 based on clinical trials showing that it could help around 60% of users reduce their body weight by at least 5% over the course of six months—and a new study shows that the tech has largely maintained those results throughout its launch into real-world settings.

To support production of VX-880 and a second clinical candidate for type 1 diabetes, VX-264, Vertex and Lonza are teaming up on process development and scale-up for the manufacturing of the drugmaker’s portfolio of stem cell-derived, fully differentiated insulin-producing islet cell therapies.